HomePress ReleaseEIN PresswireGeneral Biologicals Corporation Debuts Award-Winning Brand at Scientific Clinical Lab Expo

General Biologicals Corporation Debuts Award-Winning Brand at Scientific Clinical Lab Expo

GBC introduces two CellBio CTC most cancers detection gadgets and GB RealQuant AIO Pattern-To-Outcomes automated molecular system at AACC

HSINCHU, TAIWAN, July 23, 2023/ — Taiwanese IVD (in vitro diagnostics) producer General Biologicals Corporation (GBC) immediately unveiled two CellBio™ circulating tumor cell (CTC) most cancers detection merchandise at the American Affiliation for Clinical Chemistry Annual Scientific Assembly & Clinical Lab Expo, being held July 23-27 in Anaheim, California.

GBC is formally launching its award-winning model within the U.S. market with a extremely aggressive area of interest IVD machine and assay.

GBC’s two CTC detection methods are considered globally at the forefront of science and are used for early detection, therapy validation and remedy monitoring with speedy, accessible and inexpensive diagnostic options. The CellBio platform, which makes use of GBC proprietary iFiltration™ know-how, offers constructive management, is designed to make sure the filtration effectivity is correct, and has led to Taiwan’s first standardized CTC system. The know-how is patented and gained the 2022 Taiwan Nationwide Innovation Award.

“CellBio focuses on the detection, monitoring and therapy of most cancers metastasis. The purpose of GBC is to revolutionize the detection and therapy of most cancers by its distinctive CTC know-how and complementary therapeutics platform CellBio,” stated Frank Lin, the President of GBC. “Greater than 10 million sufferers die from most cancers annually and greater than 90 % of the deaths are attributed to metastasis. At the moment, there are not any authorized therapies that particularly goal the metastatic course of. Concentrating on CTCs with novel therapeutics may probably have a big affect on most cancers metastases and affected person final result.”

Among the many benefits of the CellBio system are detection from 7.5-mL blood samples with excessive specificity, sensitivity and most cancers seize price, full inside 90 minutes. The system applies to most cancers screening, analysis, monitoring and prognosis; offers optimum therapy; and improves the standard of life for sufferers. The variety of CTCs within the blood may be fully monitored in the course of the non-invasive sampling course of, and the seize price of greater than 90 % of most cancers cells is best than the business norm.

The CellBio FX10 can work with 10 samples at a time with a full-color contact display, whereas CellBio a2000 can detect two samples at a time in small-space labs. GBC has already gathered greater than 8,000 samples, leading to good efficacy. In line with BBC analysis, the worldwide liquid biopsy marketplace for most cancers purposes was US$1.7 billion in 2020 and is anticipated to develop at a compound annual progress price of fifty.7 %, reaching a forecasted dimension of US$13.6 billion by 2025. Main market segments embody bladder, breast, colon, gynecology-related cancers, lung most cancers, pan-cancer and prostate most cancers.

Along with CTC methods, GBC introduces the Samples-To-Outcomes automated All-in-One molecular system, GB RealQuant® AIO. The system consolidates extraction, amplification and detection in a single easy-to-use built-in instrument, offering quick and dependable outcomes inside 2 hours with excessive flexibility. The system works with all GB RealQuant HBV, HCV and HPV Kits.

For extra details about GBC, go to


Media contact

Frank Lin, GBC President, (03)577-9221,

Frank Lin
General Biologicals Corporation


Most Popular